Ascendis Pharma A/S (NASDAQ:ASND - Free Report) - Equities research analysts at HC Wainwright issued their Q3 2026 EPS estimates for shares of Ascendis Pharma A/S in a research note issued to investors on Thursday, August 27th. HC Wainwright analyst M. Kapoor forecasts that the biotechnology company will earn $1.16 per share for the quarter. HC Wainwright currently has a "Buy" rating and a $345.00 target price on the stock. The consensus estimate for Ascendis Pharma A/S's current full-year earnings is $3.90 per share. HC Wainwright also issued estimates for Ascendis Pharma A/S's Q4 2026 earnings at $1.66 EPS, FY2026 earnings at $3.93 EPS, Q1 2027 earnings at $1.76 EPS, Q2 2027 earnings at $2.48 EPS, Q3 2027 earnings at $3.20 EPS, Q4 2027 earnings at $4.42 EPS and FY2027 earnings at $11.88 EPS.
ASND has been the subject of a number of other reports. Weiss Ratings upgraded Ascendis Pharma A/S from a "sell (d)" rating to a "hold (c)" rating in a report on Wednesday, July 15th. Evercore restated an "outperform" rating and set a $329.00 price objective on shares of Ascendis Pharma A/S in a research note on Friday, May 15th. Oppenheimer reaffirmed an "outperform" rating on shares of Ascendis Pharma A/S in a report on Tuesday, June 9th. BMO Capital Markets initiated coverage on shares of Ascendis Pharma A/S in a research note on Tuesday, August 18th. They set an "outperform" rating and a $319.00 target price for the company. Finally, Jefferies Financial Group reissued a "buy" rating and set a $333.00 target price on shares of Ascendis Pharma A/S in a report on Thursday, August 13th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, Ascendis Pharma A/S has a consensus rating of "Buy" and an average target price of $302.68.
Read Our Latest Stock Analysis on Ascendis Pharma A/S
Ascendis Pharma A/S Stock Performance
NASDAQ:ASND opened at $247.91 on Monday. The company has a quick ratio of 2.32, a current ratio of 2.99 and a debt-to-equity ratio of 0.27. The business's 50 day moving average is $255.74 and its two-hundred day moving average is $239.20. Ascendis Pharma A/S has a 52 week low of $186.05 and a 52 week high of $282.15. The company has a market cap of $15.46 billion, a PE ratio of 19.23 and a beta of 0.39.
Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its quarterly earnings results on Friday, August 14th. The biotechnology company reported $1.03 EPS for the quarter, missing analysts' consensus estimates of $1.71 by ($0.68). Ascendis Pharma A/S had a return on equity of 32.54% and a net margin of 70.99%.The firm had revenue of $387.22 million during the quarter, compared to analyst estimates of $376.75 million.
Institutional Investors Weigh In On Ascendis Pharma A/S
A number of hedge funds have recently made changes to their positions in ASND. Cetera Investment Advisers bought a new position in Ascendis Pharma A/S in the 2nd quarter worth approximately $552,000. Rhumbline Advisers raised its stake in Ascendis Pharma A/S by 4.0% during the 2nd quarter. Rhumbline Advisers now owns 1,441 shares of the biotechnology company's stock valued at $249,000 after acquiring an additional 55 shares in the last quarter. Daiwa Securities Group Inc. raised its stake in Ascendis Pharma A/S by 66.2% during the 2nd quarter. Daiwa Securities Group Inc. now owns 3,737 shares of the biotechnology company's stock valued at $645,000 after acquiring an additional 1,488 shares in the last quarter. Qube Research & Technologies Ltd boosted its position in Ascendis Pharma A/S by 83.4% during the 2nd quarter. Qube Research & Technologies Ltd now owns 201,044 shares of the biotechnology company's stock worth $34,700,000 after acquiring an additional 91,412 shares during the period. Finally, Squarepoint Ops LLC acquired a new position in Ascendis Pharma A/S during the 2nd quarter worth $897,000.
Insider Transactions at Ascendis Pharma A/S
In other news, Director Jean Jacques Bienaime bought 2,000 shares of Ascendis Pharma A/S stock in a transaction on Friday, August 14th. The stock was purchased at an average cost of $246.33 per share, with a total value of $492,660.00. Following the purchase, the director directly owned 2,900 shares of the company's stock, valued at approximately $714,357. This trade represents a 222.22% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 40.00% of the stock is owned by insiders.
About Ascendis Pharma A/S
(
Get Free Report)
Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.
The company's lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Ascendis Pharma A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascendis Pharma A/S wasn't on the list.
While Ascendis Pharma A/S currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
